Getting the Right Diagnosis and Understanding the Pathology

Because DNAJC21-related SDS is so rare, getting to a definitive diagnosis often feels like a journey through several layers of testing. Understanding the “pathology”—the specific changes in the cells and genes—is the key to moving from a suspected diagnosis to a confirmed one. This process involves looking at the blueprint of DNA and the actual “factory floor” of the bone marrow ^[1][2].

The Genetic Blueprint

To have DNAJC21-related SDS, a patient typically must have biallelic mutations. This means both copies of the DNAJC21 gene (one inherited from each parent) are not working correctly ^[3].

• In Trans: Doctors look for mutations “in trans,” meaning one was inherited from the mother and one from the father ^[1].
• The Limits of Panels: Many standard “bone marrow failure panels” created just a few years ago did not include the DNAJC21 gene ^[4]. If an older panel was negative, a Whole Exome Sequencing (WES) or Whole Genome Sequencing (WGS) might be needed to find these specific variants ^[4][5]. However, even WES/WGS can miss structural variants or deep intronic variants.
• VUS and RNA: Sometimes, a genetic test finds a “variant of uncertain significance” (VUS). A VUS does not automatically establish a diagnosis. Doctors may use RNA sequencing to see if the mutation causes the cell to “skip” important parts of the gene (like exon 7 skipping), integrating this functional evidence to confirm pathogenicity ^[1][6].

Demystifying the Bone Marrow Report

A bone marrow biopsy is a “snapshot” of how the body is producing blood cells. The report can be full of complex terms ^[2][7]:

• Hypocellularity (Hypoplastic Marrow): There are fewer blood-forming cells than expected. The marrow may look “empty” or replaced by fat cells ^[3][8].
• Pancytopenia: A term for low counts in all three major blood cell types: red cells, white cells, and platelets ^[3].
• Defective Megakaryopoiesis: Problems making megakaryocytes, the large cells that produce platelets. In some DNAJC21 cases, these cells may be few in number or abnormally shaped ^[9][10].
• Dysplasia: This means the cells look “weird” or malformed. While some dysplasia can occur in inherited marrow failure without necessarily meaning leukemia, an experienced hematopathologist must interpret it ^[11].
• Blast Percentage: Immature “blast” cells below 5% are typical of a non-acute-leukemia marrow. However, a normal blast percentage does not entirely rule out MDS; it must be interpreted with cytogenetics, counts, and cellular morphology ^[12].

Somatic Mutations: Clonal Evolution

Beyond the inherited (germline) mutations, bone marrow cells can pick up new mutations over time. These are called somatic mutations or clones.

In the more common SBDS-related SDS, mutations like EIF6 or del(20q) are heavily studied, but their meaning in DNAJC21 disease is not fully established.

• EIF6 / del(20q): In classic SDS, these are sometimes considered adaptive or “rescue” events ^[13][14]. However, they still require expert monitoring, as a single clone never rules out cancer risk entirely.
• TP53: These mutations disable the cell’s “safety checks.” The appearance of biallelic TP53 alterations is a concerning sign of a higher risk for MDS or AML and requires very close monitoring ^[15][16]. It is important to know that TP53 is concerning, but not an automatic leukemia diagnosis or an immediate transplant indication on its own. Do not infer cancer risk from raw genetic files; these require expert interpretation.

A Conditional Diagnostic Checklist

To ensure a complete diagnostic picture, your specialist team may consider the following conditional items based on symptoms, age, and previous results. (Not every patient requires every test):

• [ ] Biallelic DNAJC21 Variants: Pathogenic mutations confirmed “in trans” via parental testing ^[1].
• [ ] Marrow Cellularity & Lineage: Assessment of red, white, and platelet-producing cells ^[2].
• [ ] Blast Percentage: Checked to ensure immature cells are within expected ranges ^[12].
• [ ] Cytogenetics (Karyotype/FISH): Checking for chromosome changes ^[17].
• [ ] Somatic Myeloid Panel (NGS): Checking for acquired clones like TP53 or EIF6 ^[15].
• [ ] Differential Rule-Outs: “Chromosome breakage” test (Fanconi Anemia) or “telomere length” test (Dyskeratosis Congenita) ^[2][8].